Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration : Long-term retinal changes under anti-vascular endothelial growth factor treatment.


Journal

Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 09 09 2019
accepted: 08 07 2020
pubmed: 8 8 2020
medline: 13 2 2021
entrez: 8 8 2020
Statut: ppublish

Résumé

The aim of this study was to assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term follow-up and to evaluate morphological markers potentially influencing prognosis. A total of 18 eyes of 18 patients with neovascular AMD were examined subsequent to completion of the Avastin Versus Lucentis in Age Related Macular Degeneration (MANTA) study following a mean period of 84 months (range 69-93 months). After receiving a loading dose of 3 intravitreal anti-VEGF injections subsequent to baseline of the MANTA study, patients were treated as needed (pro re nata, PRN). Functional and morphological changes were assessed, the latter using spectral domain optical coherence tomography (SD-OCT). Retinal/RPE atrophy generally increased significantly during follow-up compared to baseline (fibrosis 28% vs. 89%, p = 0.0001, geographic atrophy, GA 0% vs. 67%, p = 0.0002, RPE porosity 61% vs. 100%, p = 0.009) whereas regenerative alterations tendentially increased until 3 months and then subsequently declined until the last visit (RPE thickening 28% vs. 11%, p = 0.22 and intraretinal hyperreflective foci 89% vs. 78%, p = 0.39). Atrophic alterations of the retina and RPE are progressive and may partly be induced by anti-VEGF. Morphological findings may aid in the identification of prognostic markers in the progression of neovascular AMD. This could lead to a more targeted education of affected patients.

Identifiants

pubmed: 32761460
doi: 10.1007/s00508-020-01718-6
pii: 10.1007/s00508-020-01718-6
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Retinal Pigments 0
Vascular Endothelial Growth Factor A 0
Ranibizumab ZL1R02VT79

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123-130

Références

Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology. 1992;99(6):933–43.
doi: 10.1016/S0161-6420(92)31871-8
Friedman DS, O’Colmain BJ, Munoz B. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–72.
doi: 10.1001/archopht.1941.00870100042005
Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.
doi: 10.1016/j.ophtha.2012.04.015
Tufail A, Patel PJ, Egan C, Hykin P, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicenter randomised double masked study. BMJ. 2010; https://doi.org/10.1136/bmj.c2459 .
doi: 10.1136/bmj.c2459 pubmed: 20538634
Busbee BG, Ho AC, Brown DM, HARBOR Study Group.. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–56.
doi: 10.1016/j.ophtha.2012.10.014
Chang TS, Bressler NM, Fine JT, MARINA Study Group, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460–9.
doi: 10.1001/archopht.125.11.1460
Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83.
doi: 10.1016/j.ajo.2007.01.028
CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.
doi: 10.1056/NEJMoa1102673
IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.
doi: 10.1016/j.ophtha.2012.04.015
Regatieri CV, Branchini L, Fujimoto JG, et al. Choroidal imaging using spectral-domain optical coherence tomography. Retina. 2012;32:865–76.
doi: 10.1097/IAE.0b013e318251a3a8
Regatieri CV, Branchini L, Duker JS. The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2011;42:S56–66.
doi: 10.3928/15428877-20110627-05
Kumar N, Mrejen S, Fung AT, et al. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology. 2013;120:334–41.
doi: 10.1016/j.ophtha.2012.07.076
Grunwald JE, Daniel E, Huang J. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61.
doi: 10.1016/j.ophtha.2013.08.015
Schütze C, Wedl M, Baumann B, et al. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:1100–14.
doi: 10.1016/j.ajo.2015.02.020
Grunwald JE, Pistilli M, Ying GS, et al. Comparison of age-related macular degeneration treatments trials research group. Incidence and growth of geographic atrophy during 5 years of comparison of Age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104.
doi: 10.1016/j.ophtha.2016.09.012
Krebs I, Schmetterer L, Boltz A, MANTA Research Group, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266–71.
doi: 10.1136/bjophthalmol-2012-302391
Schmitz-Valckenberg S, Fleckenstein M, Göbel AP, et al. Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:1–6.
doi: 10.1167/iovs.10-5619
Bird AC, Phillips RL, Hageman GS. Geographic atrophy: a histopathological assessment. JAMA Ophthalmol. 2014;132:338–45.
doi: 10.1001/jamaophthalmol.2013.5799
Jaffe GJ, Martin DF, Toth CA, et al. Comparison of age-related macular degeneration treatments trials research group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:1860–70.
doi: 10.1016/j.ophtha.2013.01.073
Thavikulwat AT, Jacobs-El N, Kim JS, Agrón E, et al. Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2017;1:34–41.
doi: 10.1016/j.oret.2016.09.005
Tsuboi S, Pederson JE, Toris CB. Functional recovery of retinal pigment epithelial damage in experimental retinal detachment. Invest Ophthalmol Vis Sci. 1987;28(11):1788–94.
pubmed: 3667150
Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2011;118:687–93.
doi: 10.1016/j.ophtha.2010.08.010
Lee JY, Folgar FA, Maguire MG. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2014;121:2423–31.
doi: 10.1016/j.ophtha.2014.06.013
Zweifel SA, Engelbert M, Laud K, et al. Outer retinal tubulation a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127:1596–602.
doi: 10.1001/archophthalmol.2009.326
Curcio CA, Zanzottera EC, Ach T, et al. Activated retinal pigment epithelium, an optical coherence tomography biomarker for progression in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58(6):211–26.

Auteurs

Christian Ebner (C)

Department of Ophthalmology, Hietzing Hospital, Wolkersbergenstraße 1, Pavillon 2a and 2b, 1130, Vienna, Austria.
Karl Landsteiner Institute for Process Optimization and Quality Management in Cataract Surgery, Wolkersbergenstraße 1, 1130, Vienna, Austria.

Clara Wernigg (C)

Department of Ophthalmology, Hietzing Hospital, Wolkersbergenstraße 1, Pavillon 2a and 2b, 1130, Vienna, Austria.
Karl Landsteiner Institute for Process Optimization and Quality Management in Cataract Surgery, Wolkersbergenstraße 1, 1130, Vienna, Austria.

Christopher Schütze (C)

Department of Ophthalmology, Hietzing Hospital, Wolkersbergenstraße 1, Pavillon 2a and 2b, 1130, Vienna, Austria.
Karl Landsteiner Institute for Process Optimization and Quality Management in Cataract Surgery, Wolkersbergenstraße 1, 1130, Vienna, Austria.

Birgit Weingessel (B)

Department of Ophthalmology, Hietzing Hospital, Wolkersbergenstraße 1, Pavillon 2a and 2b, 1130, Vienna, Austria.
Karl Landsteiner Institute for Process Optimization and Quality Management in Cataract Surgery, Wolkersbergenstraße 1, 1130, Vienna, Austria.

Pia-Veronika Vécsei-Marlovits (PV)

Department of Ophthalmology, Hietzing Hospital, Wolkersbergenstraße 1, Pavillon 2a and 2b, 1130, Vienna, Austria. veronika.vecsei-marlovits@wienkav.at.
Karl Landsteiner Institute for Process Optimization and Quality Management in Cataract Surgery, Wolkersbergenstraße 1, 1130, Vienna, Austria. veronika.vecsei-marlovits@wienkav.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH